Perioperative and Oncological Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis of Rectal Origin
© 2023. The Society for Surgery of the Alimentary Tract..
BACKGROUND: The peritoneum is a common metastatic site of colorectal cancer (CRC) and associated with worse oncological outcomes. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has been shown to improve outcomes in selected patients. Studies have demonstrated significant difference in survival of patients with primary colon and rectal tumors both in local and in metastatic setting; but only few assessed outcomes of CRS/HIPEC for rectal and colon tumors. We studied the perioperative and oncological outcomes of patients undergoing CRS/HIPEC for rectal cancer.
METHODS: A retrospective analysis of a prospectively maintained database between 2009 and 2021 was performed.
RESULTS: 199 patients underwent CRS/HIPEC for CRC. 172 patients had primary colon tumors and 27 had primary rectal tumors. Primary rectal location was associated with longer surgery (mean 4.32, hours vs 5.26 h, p = 0.0013), increased blood loss (mean 441cc vs 602cc, p = 0.021), more blood transfusions (mean 0.77 vs 1.37units, p = 0.026) and longer hospitalizations (mean 10 days vs 13 days, p = 0.02). Median disease-free survival (DFS) was shorter in rectal primary group; 7.03 months vs 10.9 months for colon primaries (p = 0.036). Overall survival was not statistically significant; 53.2 months for rectal and 60.8 months for colon primary tumors. Multivariate analysis indicated origin (colon vs rectum) and Peritoneal Cancer Index to be independently associated with DFS.
CONCLUSIONS: Patients with rectal carcinoma undergoing CRS/HIPEC for peritoneal metastasis had worse peri-operative and oncological outcomes. Overall survival was excellent in both groups. This data may be used for risk stratification when considering CRS/HIPEC for patients with rectal primary.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract - 27(2023), 11 vom: 01. Nov., Seite 2506-2514 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Benvenisti, Haggai [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 21.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11605-023-05833-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362233268 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362233268 | ||
| 003 | DE-627 | ||
| 005 | 20240321235445.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11605-023-05833-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1338.xml |
| 035 | |a (DE-627)NLM362233268 | ||
| 035 | |a (NLM)37726508 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Benvenisti, Haggai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Perioperative and Oncological Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis of Rectal Origin |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 21.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Society for Surgery of the Alimentary Tract. | ||
| 520 | |a BACKGROUND: The peritoneum is a common metastatic site of colorectal cancer (CRC) and associated with worse oncological outcomes. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has been shown to improve outcomes in selected patients. Studies have demonstrated significant difference in survival of patients with primary colon and rectal tumors both in local and in metastatic setting; but only few assessed outcomes of CRS/HIPEC for rectal and colon tumors. We studied the perioperative and oncological outcomes of patients undergoing CRS/HIPEC for rectal cancer | ||
| 520 | |a METHODS: A retrospective analysis of a prospectively maintained database between 2009 and 2021 was performed | ||
| 520 | |a RESULTS: 199 patients underwent CRS/HIPEC for CRC. 172 patients had primary colon tumors and 27 had primary rectal tumors. Primary rectal location was associated with longer surgery (mean 4.32, hours vs 5.26 h, p = 0.0013), increased blood loss (mean 441cc vs 602cc, p = 0.021), more blood transfusions (mean 0.77 vs 1.37units, p = 0.026) and longer hospitalizations (mean 10 days vs 13 days, p = 0.02). Median disease-free survival (DFS) was shorter in rectal primary group; 7.03 months vs 10.9 months for colon primaries (p = 0.036). Overall survival was not statistically significant; 53.2 months for rectal and 60.8 months for colon primary tumors. Multivariate analysis indicated origin (colon vs rectum) and Peritoneal Cancer Index to be independently associated with DFS | ||
| 520 | |a CONCLUSIONS: Patients with rectal carcinoma undergoing CRS/HIPEC for peritoneal metastasis had worse peri-operative and oncological outcomes. Overall survival was excellent in both groups. This data may be used for risk stratification when considering CRS/HIPEC for patients with rectal primary | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cytoreductive surgery | |
| 650 | 4 | |a HIPEC | |
| 650 | 4 | |a Rectal Cancer | |
| 700 | 1 | |a Shiber, Mai |e verfasserin |4 aut | |
| 700 | 1 | |a Assaf, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Shovman, Yehuda |e verfasserin |4 aut | |
| 700 | 1 | |a Laks, Shachar |e verfasserin |4 aut | |
| 700 | 1 | |a Elbaz, Nadav |e verfasserin |4 aut | |
| 700 | 1 | |a Mor, Eyal |e verfasserin |4 aut | |
| 700 | 1 | |a Zippel, Douglas |e verfasserin |4 aut | |
| 700 | 1 | |a Nissan, Aviram |e verfasserin |4 aut | |
| 700 | 1 | |a Ben-Yaacov, Almog |e verfasserin |4 aut | |
| 700 | 1 | |a Adileh, Mohammad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract |d 1997 |g 27(2023), 11 vom: 01. Nov., Seite 2506-2514 |w (DE-627)NLM096454490 |x 1873-4626 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2023 |g number:11 |g day:01 |g month:11 |g pages:2506-2514 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11605-023-05833-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2023 |e 11 |b 01 |c 11 |h 2506-2514 | ||